---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-076474"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:31:48.967540+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca initiates global Phase 3 SEACRAFT-2 trial for naporafenib + trametinib in NRAS-mutant melanoma

## Summary
- SEACRAFT-2 evaluates pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib vs trametinib alone.
- Stage 1 of the Phase 3 trial is expected to yield a randomized data readout in 2025.
- Trial targets NRAS-mutant melanoma, a setting with limited approved targeted therapies.
- Initiation marks the first Phase 3 trial for Erasca's wholly owned candidate naporafenib.

## SEC filing metadata
- accession: 0000950170-24-076474
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/0000950170-24-076474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/eras-20240618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-076474
- JSON: https://secwatch.observer/filing/0000950170-24-076474.json
- Plain text: https://secwatch.observer/filing/0000950170-24-076474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.